tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Protagonist Therapeutics: Buy Rating Backed by Promising Drug Assets and Strategic Partnerships
PremiumRatingsProtagonist Therapeutics: Buy Rating Backed by Promising Drug Assets and Strategic Partnerships
19d ago
Protagonist Therapeutics initiated with an Outperform at Leerink
Premium
The Fly
Protagonist Therapeutics initiated with an Outperform at Leerink
19d ago
Protagonist Therapeutics announces icotrokinra application submitted to EMA
Premium
The Fly
Protagonist Therapeutics announces icotrokinra application submitted to EMA
20d ago
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment
PremiumCompany AnnouncementsProtagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment
2M ago
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP
Premium
The Fly
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP
2M ago
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
Premium
Ratings
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
2M ago
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
PremiumCompany AnnouncementsProtagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
2M ago
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
Premium
Ratings
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
2M ago
Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
Premium
Ratings
Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100